aidsmap news storyA first-line antiretroviral regimen containing dolutegravir reduces a high viral load faster than one containing bictegravir, and the effect was especially noticeable in people with the highest viral load, French researchers reported at AIDS 2026.
The findings have implications for the choice of first-line regimen in people with a high viral load, and may also be important for preserving immune function and restricting the size of the HIV reservoir, Dr Antoine Chéret of the University of French West Indies told the conference.
A second study presented at AIDS 2026, the randomised In VOGUE trial, showed that dolutegravir/lamivudine (Dovato) was non-inferior to bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy) in previously untreated adults with HIV.
Read the full news story here.
aidsmap news story
A first-line antiretroviral regimen containing dolutegravir reduces a high viral load faster than one containing bictegravir, and the effect was especially noticeable in people with the highest viral load, French researchers reported at AIDS 2026.
The findings have implications for the choice of first-line regimen in people with a high viral load, and may also be important for preserving immune function and restricting the size of the HIV reservoir, Dr Antoine Chéret of the University of French West Indies told the conference.
A second study presented at AIDS 2026, the randomised In VOGUE trial, showed that dolutegravir/lamivudine (Dovato) was non-inferior to bictegravir/tenofovir alafenamide/emtricitabine (Biktarvy) in previously untreated adults with HIV.
Read the full news story here.
